Skip to main content

ACR2021 - Day5a

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim Potpourri of Biosimilar Trials: Dr. Jonathan Kay Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.